<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04340596</url>
  </required_header>
  <id_info>
    <org_study_id>ACTG A5386</org_study_id>
    <secondary_id>38639</secondary_id>
    <nct_id>NCT04340596</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption</brief_title>
  <official_title>A Phase I Clinical Trial of the Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rockefeller University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ImmunityBio, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and efficacy of N-803, an&#xD;
      IL-15 superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to&#xD;
      induce HIV-1 control during analytic treatment interruption (ATI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will evaluate the safety, tolerability, and efficacy of N-803, an IL-15&#xD;
      superagonist, with or without combination broadly neutralizing antibodies (bNAbs), to induce&#xD;
      HIV-1 control during analytic treatment interruption (ATI).&#xD;
&#xD;
      Participants will be screened for eligibility and undergo leukapheresis, and a subset will&#xD;
      also undergo optional rectal biopsy and/or lymph node fine needle aspirations (FNAs) (Step&#xD;
      1).&#xD;
&#xD;
      After pre-entry and determination of eligibility in Step 1, participants will be randomized&#xD;
      before Step 2 entry to either the N-803 only arm (Arm A) or the N-803 with combination bNAbs&#xD;
      arm (Arm B):&#xD;
&#xD;
        -  Arm A will receive a dose of N-803, 6 mcg/kg, subcutaneously 1 week after Step 2 entry&#xD;
           and then every 3 weeks for a total of eight doses (during the first 22 weeks).&#xD;
&#xD;
        -  Arm B will receive the following (during the first 22 weeks):&#xD;
&#xD;
             -  Combination bNAb at Step 2 entry with VRC07-523LS dosed at 20 mg/kg and 10-1074&#xD;
                dosed at 30 mg/kg, intravenously;&#xD;
&#xD;
             -  A dose of N-803, 6 mcg/kg, subcutaneously 1 week after Step 2 entry and then every&#xD;
                3 weeks for a total of eight doses;&#xD;
&#xD;
             -  A second dose of 10-1074 at week 9 of Step 2 dosed at 30 mg/kg, intravenously&#xD;
&#xD;
      After completing randomized treatment (Step 2), participants will interrupt antiretroviral&#xD;
      therapy (ART) (Step 3) and will be followed closely to monitor for indications for&#xD;
      reinitiation of ART (Step 4).&#xD;
&#xD;
      After Step 2 entry, most participants will be followed for approximately 100 weeks across the&#xD;
      remaining three study steps (i.e., Steps 2, 3, and 4).&#xD;
&#xD;
      Step 1 will last up to 90 days, Step 2 will last approximately 52 weeks (study intervention),&#xD;
      Step 3 will last up to 24 weeks (ATI), and Step 4 will last 24 weeks (ART restart).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2021</start_date>
  <completion_date type="Anticipated">August 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of a Grade ≥3 adverse event (AE) that is at least possibly related to N-803, as judged by the Clinical Management Committee (CMC)</measure>
    <time_frame>Step 2 week 1 to week 52</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of N-803 doses completed</measure>
    <time_frame>From step 2 week 1 to step 2 week 22</time_frame>
    <description>Eight doses of N-803 are scheduled at the distinct time points listed in Time Frame. At each timepoint, dose completion status is recorded. Number of N-803 doses completed is the total number completed doses across all 8 timepoints.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants requiring dose reduction</measure>
    <time_frame>From step 2 week 4 to step 2 week 22</time_frame>
    <description>Eight doses of N-803 are scheduled at distinct time points (Step 2 weeks 1, 4, 7, 10, 13, 16, 19 and 22). Proportion of participants requiring dose reduction is calculated as the number of participants who receive a reduced dose of N-803 at any of the 7 scheduled doses occurring after the first dose, divided by the total number of participants receiving N-803.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with plasma HIV-1 RNA &lt;200 copies/mL 8 weeks after interruption of ART</measure>
    <time_frame>At step 3 week 8</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a Grade ≥2 AE without regard to relationship to study treatment</measure>
    <time_frame>Study entry to participant's last study visit, at approx. study week 100</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a Grade ≥2 AE that is at least possibly related to N-803, as judged by the CMC</measure>
    <time_frame>Step 2 week 1 to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of a Grade ≥2 AE that is at least possibly related to VRC07-523LS or 10-1074</measure>
    <time_frame>Step 2 week 0 to week 52</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-associated HIV-1 RNA</measure>
    <time_frame>At Step 2 weeks 0, 1, 7, 13, 19, 22, 26 and 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of HIV-1 reservoir (dQVOA)</measure>
    <time_frame>At Step 2 weeks 0, 1, 7, 13, 19, 22, 26 and 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of plasma viremia by HIV-1 single copy assay</measure>
    <time_frame>At step 1 pre-entry evaluation and step 2 weeks 0, 1, 7, 13, 22 and 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of intact proviral DNA</measure>
    <time_frame>At Step 2 weeks 0, 1, 7, 13, 19, 22, 26 and 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total HIV-1 DNA</measure>
    <time_frame>At Step 2 weeks 0, 1, 7, 13, 19, 22, 26 and 32</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with plasma HIV-1 RNA &lt;200 copies/mL at 4, 12 and 24 weeks after interruption of ART in Step 3</measure>
    <time_frame>At step 3 weeks 4, 12, and 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: AUC0-τ of 10-1074</measure>
    <time_frame>At step 2 weeks 0, 1, 4, 7, 9, 10, 13, 16, 19, 22, 26, 32 and 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameters: AUC0-τ of VRC07-523LS</measure>
    <time_frame>At step 2 weeks 0, 1, 4, 7, 9, 10, 13, 16, 19, 22, 26, 32 and 46</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants with antidrug antibodies</measure>
    <time_frame>At step 2 weeks 0, 1, 4, 7, 9, 10, 13, 16, 19, 22, 26, 32 and 46</time_frame>
    <description>Presence of anti-N803, anti-10-1074, and anti-VRC07-523LS antibodies</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">46</enrollment>
  <condition>HIV Infection</condition>
  <arm_group>
    <arm_group_label>Arm A: N-803 only</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive N-803 6 mcg/kg 1 week after Step 2 entry and then every 3 weeks for a total of eight doses.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B: N-803 in combination with 10-1074 and VRC07-523LS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive N-803 in combination with 10-1074 and VRC07-523LS as follows:&#xD;
At Step 2 entry:&#xD;
VRC07-523LS 20 mg/kg&#xD;
10-1074 30 mg/kg&#xD;
At Step 2, week 1: N-803 6 mcg/kg every 3 weeks for eight doses&#xD;
At Step 2, week 9: 10-1074 30 mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>N-803 (IL-15 Superagonist)</intervention_name>
    <description>Administered by subcutaneous (SQ) injection</description>
    <arm_group_label>Arm A: N-803 only</arm_group_label>
    <arm_group_label>Arm B: N-803 in combination with 10-1074 and VRC07-523LS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>VRC07-523LS</intervention_name>
    <description>Administered by intravenous (IV) infusion</description>
    <arm_group_label>Arm B: N-803 in combination with 10-1074 and VRC07-523LS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>10-1074</intervention_name>
    <description>Administered by intravenous (IV) infusion</description>
    <arm_group_label>Arm B: N-803 in combination with 10-1074 and VRC07-523LS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  HIV-1 infection&#xD;
&#xD;
          -  On ART for at least 96 weeks prior to randomization&#xD;
&#xD;
          -  On ART regimen containing an integrase inhibitor and two nucleoside reverse&#xD;
             transcriptase inhibitors (NRTIs) or dolutegravir/lamivudine for at least 6 weeks prior&#xD;
             to randomization.&#xD;
&#xD;
          -  CD4 cell count &gt;450 cells/mm^3 within 90 days prior to randomization&#xD;
&#xD;
          -  CD4 cell count nadir ≥200 cells/mm^3.&#xD;
&#xD;
          -  Plasma HIV-1 RNA levels of &lt;50 copies/mL for at least 96 weeks prior to randomization&#xD;
&#xD;
          -  Select laboratory results within 90 days of randomization&#xD;
&#xD;
          -  IC90 to 10-1074 of ≤1.5 mcg/mL, 10-1074 maximum percent inhibition (MPI) ≥98%, and&#xD;
             IC80 to VRC07-523LS of ≤1 mcg/mL on the Monogram PhenoSense assay.&#xD;
&#xD;
          -  QTcF interval ≤440 msec within 90 days prior to randomization.&#xD;
&#xD;
          -  For cisgender women and transgender men of reproductive potential, negative urine or&#xD;
             serum pregnancy test within 30 days prior to randomization&#xD;
&#xD;
          -  Cisgender women and transgender men of reproductive potential must agree to use two&#xD;
             methods of contraception, if participating in sexual activity that could lead to&#xD;
             pregnancy.&#xD;
&#xD;
          -  Cisgender men and transgender women participants engaging in sexual activity that&#xD;
             could lead to pregnancy and who are of reproductive potential must agree to use a&#xD;
             barrier method of contraception&#xD;
&#xD;
          -  Willingness to abstain from sexual intercourse or use a barrier method of&#xD;
             contraception consistently&#xD;
&#xD;
          -  Willingness to participate in an ATI.&#xD;
&#xD;
          -  Weight &gt;50 kg and &lt;115 kg.&#xD;
&#xD;
          -  Completion of pre-entry leukapheresis&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  History of AIDS-defining illness, with the exception of recurrent pneumonia.&#xD;
&#xD;
          -  History of or current clinical cardiovascular disease&#xD;
&#xD;
          -  Current clinically significant acute or chronic medical condition&#xD;
&#xD;
          -  History of HIV-associated neurocognitive disease&#xD;
&#xD;
          -  History of an HIV-associated malignancy&#xD;
&#xD;
          -  ART initiated during acute HIV infection&#xD;
&#xD;
          -  Current receipt of ART other than NRTI and integrase inhibitor.&#xD;
&#xD;
          -  Resistance to one or more drugs in two or more ARV drug classes.&#xD;
&#xD;
          -  Receipt of any therapeutic HIV vaccine or monoclonal antibody therapy (anti-HIV or&#xD;
             otherwise) at any time in the past.&#xD;
&#xD;
          -  History of prior immunoglobulin (IgG) therapy.&#xD;
&#xD;
          -  History of use of any immunomodulatory medications within 6 months prior to&#xD;
             randomization&#xD;
&#xD;
          -  Participation in another clinical study of an investigational product currently or&#xD;
             within past 12 weeks&#xD;
&#xD;
          -  Breastfeeding or pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Timothy Wilkin, MD, MPH</last_name>
    <role>Study Chair</role>
    <affiliation>Weill Medical College of Cornell University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center CRS</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aleen Khodabakhshian</last_name>
      <phone>310-557-2273</phone>
      <phone_ext>20891</phone_ext>
      <email>akhodabakhshian@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCSD Antiviral Research Center CRS (Site ID: 701)</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steven Hendrickx, R.N.</last_name>
      <phone>619-543-6968</phone>
      <email>smhendrickx@health.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ucsf Hiv/Aids Crs</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elvira Gomez</last_name>
      <phone>415-476-4082</phone>
      <phone_ext>106</phone_ext>
      <email>elvira.gomez@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Whitman-Walker Institute, Inc. CRS (Site ID: 31791)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Avery A Wimpelberg, B.A., CCRC</last_name>
      <phone>202-797-3589</phone>
      <email>awimpelberg@whitman-walker.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University CRS</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baiba Berzins, M.P.H.</last_name>
      <phone>312-695-5012</phone>
      <email>Baiba@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital CRS (MGH CRS) (Site ID: 101)</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amy Sbrolla, R.N., B.S.N., A.C.R.N.</last_name>
      <phone>1-617-7265598</phone>
      <email>asbrolla@mgh.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University Therapeutics (WT) CRS</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110-1010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael K Klebert</last_name>
      <phone>314-747-1098</phone>
      <email>mklebert@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Uptown CRS (Site ID: 7803)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Fry, M.S.N., FNP</last_name>
      <phone>212-746-4166</phone>
      <email>ref2007@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chapel Hill CRS (Site ID: 3201)</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Becky Straub, B.S.N., M.P.H., R.N.</last_name>
      <phone>1-919-843-9975</phone>
      <email>bstraub@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Case Clinical Research Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane Baum, R.N.</last_name>
      <phone>216-844-2546</phone>
      <email>baum.jane@clevelandactu.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Penn Therapeutics, CRS (Site ID: 6201)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Amanda Baer, M.B., MBS</last_name>
      <phone>215-349-5023</phone>
      <email>Baer2@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>https://rsc.niaid.nih.gov/clinical-research-sites/manual-expedited-reporting-adverse-events-daids</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>March 23, 2020</study_first_submitted>
  <study_first_submitted_qc>April 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2020</study_first_posted>
  <last_update_submitted>November 12, 2021</last_update_submitted>
  <last_update_submitted_qc>November 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data that underlie results in the publication, after deidentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Beginning 3 months following publication and available throughout period of funding of the AIDS Clinical Trials Group by NIH.</ipd_time_frame>
    <ipd_access_criteria>With whom?&#xD;
Researchers who provide a methodologically sound proposal for use of the data that is approved by the AIDS Clinical Trials Group.&#xD;
For what types of analyses?&#xD;
To achieve aims in the proposal approved by the AIDS Clinical Trials Group.&#xD;
By what mechanism will data be made available?&#xD;
Researchers may submit a request for access to data using the AIDS Clinical Trials Group &quot;Data Request&quot; form at: https://actgnetwork.org/about-actg/templates-and-forms. Researchers of approved proposals will need to sign an AIDS Clinical Trials Group Data Use Agreement before receiving the data.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

